September 11, 2019 08:39 AM EDTUpdated 05:31 PM

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Natalie Grover

Reporter

Ahead of the keenly anticipated independent panel set to discuss Aimmune’s peanut allergy immunotherapy on Friday, FDA staff issued a predictable review on Wednesday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Natalie Grover

Reporter

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win

No sur­pris­es in FDA staff re­view for Aim­mune peanut al­ler­gy ther­a­py — fo­cus re­mains on safe­ty, tol­er­a­bil­i­ty pro­file

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win